Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05

A legfontosabb adatok

Ki végzi
Tarsus Pharmaceuticals, Inc.
Hol
Boston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
30 fő vett részt
Kezdés
2022. dec. 12.
Befejezés
2024. jún. 26.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Low Dose TP-05
  • High Dose TP-05
  • Placebo Comparator
A regiszteradat frissítve
2024. szeptember 19.

Ki vehet részt

Életkor
18 év – 59 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • Participant must be 18 to 59 years of age inclusive, at the time of signing the informed consent
  • Participants who are overtly healthy as determined by medical evaluation including having no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination
  • Participants who are non- or ex-smokers
  • Willingness to comply with all study procedures and availability for the duration of the study
  • BMI within the range 18 - 32 kg/m2
  • Willingness to comply with contraceptive requirements
  • Capable of giving signed informed consent

Ki nem vehet részt

  • Any clinically significant illness in the 28 days prior to study treatment administration
  • Use of any non-prescription or prescription drugs (with the exception of hormonal contraceptives, hormone replacement therapy, acetaminophen) in the 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to study treatment administration
  • Use of St. John's wort in the 28 days prior to study treatment administration
  • Intake of lotilaner in the 6 months prior to study treatment administration
  • Treatment with an investigational drug within 30 days or 5 times the half-life (whichever is longer) prior to Screening
  • History of live attenuated vaccine within 4 weeks prior to randomization or requirement to receive these vaccinations at any time during the study
  • Blood donation of approximately 500 mL within 56 days prior to Screening
  • Plasma donation within 7 days prior to Screening
  • History of significant hypersensitivity to lotilaner or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
  • Presence or history of significant gastrointestinal, metabolic, liver or kidney disease, or surgery that may affect drug bioavailability (excluding appendectomy)
  • History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease
  • Have a history of malignancy (or active malignancy), with the exception of treated basal cell or squamous cell carcinoma
  • Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse
  • Known history of chronic infectious disease
  • History of allergy to surgical tape, hydrocolloid, or dressing
  • History of severe reactions to tick bites (granuloma or systemic reactions)
  • Female who is pregnant according to the serum pregnancy test at Screening or prior to study treatment administration
  • Any other clinically significant abnormalities in laboratory test results at Screening that would, in the opinion of the Investigator, increase the participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data
  • Female who is lactating at Screening
  • Presence of clinically significant ECG abnormalities at Screening, as defined by the Investigator

Helyszínek itt: Egyesült Államok

  • Tufts University School of MedicineBoston, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a Phase 2a, randomized, double-blind, proof-of-concept, single-center study evaluating the safety, tolerability, and whole blood concentration of TP-05 (lotilaner) in the killing of ticks after they have attached to human skin.

A vizsgálat 3 csoportja

  • Low Dose of TP-05 (lotilaner)A vizsgált kezelés

    Single Oral Low Dose of TP-05 tablet.

    Kezelés: Low Dose TP-05

  • High Dose of TP-05 (lotilaner)A vizsgált kezelés

    Single Oral High Dose of TP-05 tablet.

    Kezelés: High Dose TP-05

  • PlaceboPlacebo, összehasonlításként

    Single Oral Dose of placebo tablet.

    Kezelés: Placebo Comparator

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Single-Center, Human Tick Kill Proof-of-Concept Study Evaluating the Safety, Tolerability, and Whole Blood Concentration of TP-05 (lotilaner) in Healthy Volunteers
A regiszteradat frissítve
2024. szeptember 19.